Innate Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	53.7	66.4	70.61	84.23	103.76	136.79
Short-Term Investments	6.32	14.37	21.85	17.26	16.08	14.85
Cash & Short-Term Investments	60.03	80.77	92.46	101.49	119.84	151.64
Cash Growth	-34.61%	-12.64%	-8.90%	-15.31%	-20.97%	-30.72%
Accounts Receivable	0.36	0.65	15.23	3.08	0.85	10.59
Other Receivables	0.84	0.99	31.26	27.94	12.63	3.28
Receivables	1.2	1.64	46.49	31.02	13.47	13.87
Prepaid Expenses	2.15	2.82	5.69	4.67	2.58	6.83
Other Current Assets	1.6	0.51	3.37	2.65	2.36	1.11
Total Current Assets	64.98	85.74	148.01	139.83	138.26	173.45
Property, Plant & Equipment	4.96	5.13	6.32	8.54	10.17	11.69
Long-Term Investments	10.39	10.28	9.8	35.12	39.88	38.93
Other Intangible Assets	-	-	0.42	1.56	44.19	46.29
Long-Term Deferred Tax Assets	-	-	-	-	5.03	7.09
Other Long-Term Assets	12.61	9.9	10.64	14.25	29.97	29.97
Total Assets	92.94	111.06	175.19	199.3	267.5	307.42
Accounts Payable	4.55	7.92	8.56	13.66	14.73	20.73
Current Portion of Long-Term Debt	8.47	8.44	8.45	1.28	29.94	1.37
Current Portion of Leases	0.46	0.27	0.49	0.82	0.8	0.78
Current Income Taxes Payable	6.59	6.96	7.02	5.98	7.46	8.33
Current Unearned Revenue	7.35	8.06	13.51	16.78	19.92	13.13
Other Current Liabilities	2	1.33	1.61	2.82	7.03	1.16
Total Current Liabilities	29.43	32.98	39.64	41.34	79.89	45.49
Long-Term Debt	17.94	22.18	30.61	38.93	11.49	14.19
Long-Term Leases	0.15	0.1	0.35	1.22	2.01	2.76
Long-Term Unearned Revenue	37.15	43.95	49.65	60.91	58.41	77.53
Pension & Post-Retirement Benefits	2.67	2.73	2.44	2.55	2.98	4.18
Long-Term Deferred Tax Liabilities	-	-	-	-	5.03	7.09
Other Long-Term Liabilities	0.46	0.27	0.6	0.2	0.25	0.22
Total Liabilities	87.79	102.23	123.29	145.14	160.06	151.45
Common Stock	4.61	4.19	4.04	4.01	3.98	3.95
Additional Paid-In Capital	407.05	390.98	384.26	379.64	375.22	372.13
Retained Earnings	-407.71	-386.36	-336.89	-330.32	-272.21	-220.46
Comprehensive Income & Other	1.19	0.03	0.5	0.82	0.46	0.36
Shareholders' Equity	5.14	8.83	51.9	54.15	107.44	155.98
Total Liabilities & Equity	92.94	111.06	175.19	199.3	267.5	307.42
Total Debt	27.03	31	39.89	42.25	44.25	19.09
Net Cash (Debt)	33	49.78	52.56	59.23	75.59	132.55
Net Cash Growth	-41.38%	-5.30%	-11.26%	-21.63%	-42.98%	-33.77%
Net Cash Per Share	0.39	0.61	0.65	0.74	0.95	1.68
Filing Date Shares Outstanding	92.16	92.16	80.86	80.19	79.54	78.98
Total Common Shares Outstanding	92.16	83.83	80.86	80.19	79.54	78.98
Working Capital	35.55	52.76	108.38	98.49	58.37	127.96
Book Value Per Share	0.06	0.11	0.64	0.68	1.35	1.97
Tangible Book Value	5.14	8.83	51.49	52.6	63.25	109.69
Tangible Book Value Per Share	0.06	0.11	0.64	0.66	0.80	1.39

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q